BioCryst to Present at Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company

NanoViricides Files Quarterly Report

NanoViricides, Inc. (OTC: NNVC.OB) (the "Company"), has filed its quarterly report with the Securities ...

Avian Flu Study Finally And Fully Published

After endless toing and froing over whether two studies that demonstrated how bird flu, also known as avian H5N1 influenza, or avian flu, should be published, one of them has appeared in the latest issue of the journal Nature in its entirety. The studies show how the bird flu virus could become transmissible from mammal-to-mammal; as humans are mammals, the same would apply to humans. This is ...

After Epic Debate, Avian Flu Research Sees Light of Day

After a marathon debate over a pair of studies that show how the avian H5N1 influenza virus could become transmissible in mammals, and an unprecedented recommendation by a government review panel to block publication, one of the studies was finally and fully published today (May 3, 2012) in the journal Nature.

NanoViricides Announces Issuance of a Fundamental Patent in the USA

NanoViricides, Inc. announced today that a fundamental patent, on which the nanoviricides® technology is based, is due to be issued in the USA on May 8, 2012.